MDS Nordion and the Karpov Institute of Physical Chemistry in Moscow have agreed to study the feasibility of the institute providing the firm with a supply of molybdenum-99 (Mo-99) for the global nuclear medicine market.
Under the collaboration, MDS Nordion and the Karpov Institute will combine their respective expertise and resources to explore a commercialization plan for a long-term supply of Mo-99, according to MDS Nordion of Ottawa, Canada.
Related Reading
MDS urges Canada to restart Maple reactor project, June 12, 2009
Facing Mo-99 shortage, nuclear medicine economizes, June 11, 2009
MDS posts loss in Q2 results, June 11, 2009
MDS begins CardioGen-82 production, June 10, 2009
MDS advocates Maple reactor activation, June 1, 2009
Copyright © 2009 AuntMinnie.com
